Danaher Corporation, worth $162.7 billion, is set to announce its Q4 earnings on Jan. 28. Analysts predict a profit of $2.14 per share, unchanged from last year. For the full year, EPS is expected to rise to $7.71, up 3.1%.

Despite underperforming the S&P 500 and XLV, Danaher is cautious due to China’s policy headwinds and restrained spending. The company expects a modest recovery in bioprocessing and diagnostics, with efforts to counter China’s impacts.

After reporting Q3 results, DHR saw a 5.9% stock increase, surpassing EPS expectations. Analysts hold a bullish outlook on DHR stock, with a “Strong Buy” rating overall. The average price target is $258.24, indicating a potential upside of 9.2% from current levels.

Read more at Yahoo Finance: Here’s What to Expect From Danaher’s Next Earnings Report